LEASE by and between B9 LS HARRISON & WASHINGTON LLC, a Delaware limited liability company and PYXIS ONCOLOGY, INC., a Delaware corporationLease • October 1st, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations
THIS LEASE (this “Lease”) is entered into as of this 29th day of September, 2021 (the “Execution Date”), by and between B9 LS HARRISON & WASHINGTON LLC, a Delaware limited liability company (“Landlord”), and PYXIS ONCOLOGY, INC., a Delaware corporation (“Tenant”).
ConfidentialOpt-In, Investment and Additional Consideration Agreement • October 1st, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations
THIS AMENDMENT TO OPT-IN, INVESTMENT AND ADDITIONAL CONSIDERATION AGREEMENT (the “Amendment”) is made as of August 2, 2021, to be effective as of January 1, 2021 (“Effective Date”) as part of the License between the Parties (each as defined below).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED COLLABORATION AGREEMENT by and among...Collaboration Agreement • October 1st, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED COLLABORATION AGREEMENT (this “Agreement”) is entered into as of September 28, 2021, to be effective as of March 30, 2021 (the “Effective Date”), by and among Pyxis Oncology, Inc., a Delaware corporation, having offices at 35 CambridgePark Drive, Cambridge, MA 02140 (“Pyxis”), Alloy Therapeutics, Inc., a Delaware corporation, having offices at 44 Hartwell Avenue, Suite 2, Lexington, MA 02421 (“Alloy”), and Voxall Therapeutics, LLC, a Delaware limited liability company, having offices at 44 Hartwell Avenue, Suite 2, Lexington, MA 02421 (the “Company”). Pyxis, Alloy and the Company are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 1st, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of March, 2021, by and among Pyxis Oncology, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
